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OBJECTIVES: Economic evaluations in oncology require estimating survival bene-
fits which is used to obtain quality adjusted life years (QALYs) and incremental
cost-effectiveness ratios (ICERs). However, few guidelines exist on how survival
data should be analyzed and extrapolated to obtain full survival benefit for eco-
nomic evaluation. A recent NICE Decision Support Unit document details an algo-
rithm for selecting survival models for economic evaluations alongside clinical
trials. We use this algorithm and other published literature to demonstrate how
different models lead to varying survival estimates and how survival data can be
systematically assessed in a patient registry using patient-level data. METHODS:
Data from the National Cancer Institute’s Surveillance Epidemiology and End Re-
sults (SEER) were used. Surgical treatment for prostate cancer was used to illustrate
the methods, but the approach is transferrable to other cancers and treatment
strategies. Patients diagnosed with prostate cancer (PC) between 1991 and 2001
were included, the sample was limited to stage IV PC patients. Survival between
surgery and non-surgery group was estimated via Kaplan Meier, parametric and
semi-parametric methods. Several model fit criteria’s such as visual inspection,
log-cumulative hazard plots, Cox-Snell residuals, Akaike Information Criterion
(AIC), Bayesian Information Criterion (BIC) along with proportionality assumption
tests were used to select appropriate method and distribution. Observed and ex-
trapolated mean estimates were calculated and compared. RESULTS: Analysis in-
dicated that survival time and benefit differed based on the model selected. Our
case example demonstrated the best fit was with Weibull and exponential distri-
butions – however, consideration must also be given to the tail in any extrapolation
of the parametric distributions selected. CONCLUSIONS: Systematic analysis of
survival data is an important evaluation criterion by health technology assess-
ments. Selection of survival models must be justified using appropriate steps as
different models can yield varying estimates, and improper selection can translate
to incorrect estimation of QALYs and the resulting ICERs.
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OBJECTIVES: To investigate the merits and challenges with calibrating Bayesian
multiple treatment comparison meta-analysis (MTC) with cost-effectiveness (CE)
analysis, in particular, construction of multiple cost-effectiveness acceptability
curves and cost-effectiveness frontiers. METHODS: We calibrated a Bayesian MTC
of pharmacotherapies for chronic obstructive pulmonary disease with a Bayesian
CE markov model. We simulated 10000 observations and derived multiple cost-
effectiveness acceptability curves for each of the treatments as well as the cost-
effectiveness frontier. We separately repeated the analyses based on pair-wise
meta-analysis estimates of treatment effectiveness. We compared the two ap-
proaches with respect to precision and inferred reasonable CE thresholds.
RESULTS: The MTC approach generally yielded higher precision, and thus, had
higher certainty surrounding the inferred CE thresholds. This was especially the
case for comparisons with treatments in the extended dominance region, but close
to the cost-effective treatments. CONCLUSIONS: Calibration of Bayesian multiple
treatment comparison meta-analysis and Bayesian multiple cost-effectiveness ac-
ceptability curves appears to improve precision compared with the conventional
approach.
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OBJECTIVES: Cost-effectiveness assessment using real-life data is important to
improve health care management. We applied marginal structural models (MSMs)
to evaluate cost-effectiveness of statin therapy and medication adherence in the
secondary prevention of acute myocardial infarction (AMI), using health care ad-
ministrative databases (HADs). METHODS: This is an observational longitudinal
study based on HADs of the national health care system in Lombardy, a region in
Northern Italy with about 9 millions of inhabitants. Patients hospitalized in 2003 for
their first episode of AMI were followed until December 31, 2008, collecting data on
health care services and vital status. Persistence and adherence to statin were
measured as time-dependent variables. We adopted a net-benefit regression ap-
proach with related acceptability curves, using direct medical costs and gained
life-years as outcomes. MSMs accounted for the dynamic interactive effects be-
tween treatment and the time-varying confounders, i.e. non-fatal cardiovascular
(CV) events and others CV therapies. RESULTS: A total of 11,706 individuals (65%
men) with a mean age of 70 years, were hospitalized for their first AMI during 2003.
26% of patients died during a median follow-up time of 5 years. The mean annul
total cost per patient was €4,348 (95%CI: 4,264-4,408), 59% of which was attributable
to CV diagnosis. Statin reduced the risk of death and medication adherence af-
fected risk reduction. The incremental net-benefit of statin therapy was positive
for values of willingness to pay (WTP) equal or greater than €0. The probability
that statin therapy was cost-effective was 50% for WTP equal to €0 and about
75% for values equal or greater than €250. Medication adherence influenced
cost-effectiveness. CONCLUSIONS: MSMs can be used in economic health care
evaluations to account for time-varying confounding, trying to minimize the po-
tential biases of longitudinal observational studies. This study confirms cost-effec-
tiveness of statin therapy for secondary prevention in real-life settings and sug-
gests further investigations on adherence effects.
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OBJECTIVES: Since 2001 in Italy several regions have introduced a fixed co-pay-
ment with some differences in the amount and exemptions. The aim of the study
was to assess, through a time-series analysis, the effect of the introduction of the
co-payment on pharmaceutical consumption, using, as case study, two Italian
regions: Piemonte and Puglia. METHODS: Monthly data between January 2000 and
December 2010 related to both public and private outpatient consumption were
used in the analysis. Public consumption data were obtained from AIFA’s Medi-
cines Utilisation Monitoring Centre (OsMeD); conversely, data on private consump-
tion were obtained as difference between the total consumption (private and pub-
lic) provided by IMS Health and public consumption. The data were expressed in
Defined Daily Doses (DDD) per 1000 inhabitants. A segmented regression analysis
was performed, controlling for the autocorrelation. RESULTS: In Piemonte Region
the introduction of co-payment had an immediate significant effect on public con-
sumption with a reduction of 74 DDD per 1000 inhabitants (p-value 0.007). The
private consumption showed a significant increase of 119 DDD per 1000 inhabit-
ants (p-value 0.03) after the introduction of the co-payment. In Puglia Region the
co-payment didn’t have the expected outcome; in fact both public and private
consumption increased after the intervention. In the long term the public con-
sumption steadily grew and there was a significant reduction in private
consumption. CONCLUSIONS: The introduction of co-payment didn’t have the
expected effect in reducing the over consumption. In Piemonte Region the reduc-
tion of public consumption was balanced by the increase in private consumption
(substitution effect). In Puglia Region the co-payment resulted in a lowering of private
consumption, probably due to fewer available economic resources (income effect),
and didn’t have any effect on public consumption.
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OBJECTIVES: Insomnia is mostly treated by benzodiazepine (BZD) or Z-drugs that
are efficacious but are also associated with safety issues like dependence and re-
bound insomnia. These safety concerns may present a major public health issue,
particularly for the elderly. Prolonged-release (PR) melatonin is a non-sedative
hypnotic that has demonstrated clinically relevant efficacy on quality of sleep and
morning alertness, with a good safety profile. Several clinical trials demonstrated
that the PR-melatonin could help reduce BZD/Z-drugs consumption. The objective
is to analyze the impact of anti-BZD/Z-drug campaigns and the availability of PR-
melatonin on the consumption of BZD/Z-drugs. METHODS: Nine European coun-
tries were studied. For each one, we studied the evolution of BZD/Z-drug sales
volumes related to: the launch strategy of PR-melatonin, anti-BZD/Z drug cam-
paigns, the market uptake of PR-melatonin and its reimbursement status. The
sales differences from 2005 were interpreted graphically for BZD, Z-drugs and
PR-melatonin. RESULTS: Three types of countries were identified: -Countries
where the sales of BZD/Z-drugs decreased since 2007: Greece, Finland and Den-
mark. - Countries where the sales of BZD decreased while Z-drugs increased: Nor-
way, the Netherlands and the UK. The anti-BZD campaigns seem effective for
BZDs, but essentially resulted in the shift in prescription patterns towards Z-drugs.
- Countries where the sales of BZD were stable and Z-drugs increased resulting in
an overall increase in BZD/Z-drug sales despite anti-BZD/Z campaigns: France,
Sweden and Spain. Campaigns aiming to reduce the use of BZD/Z-drugs failed
when they were not associated with the availability and market uptake of PR-
melatonin. The reimbursement of PR-melatonin supports better penetration rates
and a higher reduction in sales for BZD/Z-drugs. The disreimbursement of BZD/Z-
drugs did not have any effect on Z-drug prescriptions, with an increase noted
during 2011. CONCLUSIONS: Policy makers wishing to change drug utilization pat-
terns should consider the availability of pharmacological alternatives.
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OBJECTIVES: A recent study[1] by the Tufts Center for the Study of Drug Develop-
ment indicated that Central Nervous System (CNS) drugs take 35% longer to de-
velop and are less likely to gain approval compared to other new prescription
medicines. Once approved in Europe, Transparency Directive 89/105/EEC requires
countries to determine pricing and reimbursement (P&R) within 180 days but this
target is not always met. This study evaluated the time required to achieve P&R and
to launch CNS products in Europe to quantify how such delays impact patients and
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companies. METHODS: We identified branded antidepressant and antipsychotic
launches between 2003 and 2010. Market authorisation dates and P&R dates were
sourced from national databases and launch dates were determined using IMS
MIDAS data. The average time between market authorisation, P&R and launch was
then calculated for fifteen European countries. RESULTS: In most countries the
identified products were not launched until P&R was secured, making it a signifi-
cant barrier to patient access. The average time taken to achieve P&R was approx-
imately 310 days, with significant variation between countries. This delay was
frequently longer than the average P&R delay seen across all therapy areas. On
average only the UK, Germany and Denmark achieved P&R within Transparency
Directive guidelines. Significant delays were seen in Portugal and France, taking on
average 550 and 610 days respectively to gain P&R. CONCLUSIONS: In addition to
known development challenges for CNS products, manufacturers experience
greater delays in securing P&R in Europe, denying patients timely access to these
drugs. Few countries comply with the current Transparency Directive[2], and if
proposed changes are implemented to reduce the delay to 120 days, even fewer will
be compliant. P&R is an additional hurdle to access that particularly impacts CNS
drugs, and stronger efforts to reduce these delays are needed.
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OBJECTIVES: Recently, there is growing evidence of inappropriate variation in use
of certain medicines. In Serbia the consumption of pentoxifylline, dihydroergotox-
ine, nicergoline, deproteinized calf blood extract (DCBE) and cinnarizine, drugs
with uncertain clinical benefit (UCB drugs), with clinical trials with little evidence
suggesting their clinical benefit, is unusually high. The aim of this study was to
analyze the consumption of UCB drugs in second largest city in Serbia – Novi Sad,
in 1984 and 2008., to compare with those in entire Serbia, Denmark and Norway,
and to examine the potential impact on population budget. METHODS: The study
included data on consumption of these medicines in 1984. and 2008., in Novi Sad.
Data were obtained from all state-owned and private pharmacies on the territory of
Novi Sad. The number of (DDD/1000 inh/day) was calculated using ATC/DDD
methodology. RESULTS: Total consumption of analyzed drugs with uncertain clin-
ical benefit in Novi Sad has surprisingly increased in 2008 (12,59DDD/TID) in com-
parison to 1984 (7.37DDD/TID). Also, their total consumption in entire Serbia in
2008. was higher than in Novi Sad (16,72DDD/TID) and even several dozens of times
higher than in Denmark and Norway (0.2DDD/TID). The money which population
spent for UCB drugs yearly was more than 90 Mill EU in Serbia Although different
administrative and educational approaches were applied in Serbia, their use not
only did not decrease, but has significantly increased throughout years.
CONCLUSIONS: These results suggest the need for putting greater efforts into ed-
ucation of general population who buys the UCB medicines in high amounts on
their own accord. The work is part of SerbianSP No41012.
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OBJECTIVES: A reimbursement prediction model was previously developed based
on a dataset of submissions to the Scottish Medicines Consortium (SMC) between
2008 and 2010. The aim was to update and re-analyze the dataset, and to test
internal and external validity of the prediction model on submissions from 2011
and 2012. METHODS: A database of submissions between January 2005 and March
2012 was created. Data of 405 applications were collected, including information on
the reimbursement decision (yes/no), clinical data and indicators of the health
economic model quality supporting the submission. The impact of these variables
was estimated with univariate and multivariate logistic regression models. The
multivariate model was identified by a backward selection procedure. Internal
validity was assessed by the area under the receiver operating characteristic (ROC)
curve. External validity was conducted and judged by a classification test to predict
the SMC decision based on 2011-2012 data. RESULTS: Out of 405 applications 226
received positive recommendation (56%) and 131 (58%) of them were reimbursed
with restriction, e.g. limited patient population or restricted time period. Based on
univariate analyses, three factors had the largest significant effect on the reim-
bursement: poor pharmacoeconomic analysis design (OR0.03), high ICER
(OR0.16) and unclear/ inferior efficacy outcomes (OR0.25). The final multivariate
model included the following further factors: antineoplastic-immunomodulating
agent (OR0.47), combination therapy (OR2.00), biological drug (OR0.16), place-
bo-uncontrolled trial (OR0.50), extended indication (OR4.24), innovative drug
(OR2.07). The area under the ROC curve was high; 87.7%. Based on the external
validation, using a model estimated on data until December 2010 and a cut-off
point of 50%, 79.8% of the predicted reimbursement decisions in 2011-2012 were
correctly classified. CONCLUSIONS: The new prediction model demonstrates in-
ternal and external validity for 2011-2012. Therefore, the model could be used as
input when further optimizing the market access strategy for products in clinical
development.
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OBJECTIVES: To compare Dutch and Swedish drug reimbursement decisions and
to investigate the available evidence, used criteria, outcomes and transparency of
the decision-making process.METHODS:We investigated Dutch and Swedish pub-
licly available drug reimbursement dossiers from 2005 until July 2011. Applications
and outcomes were compared and classified into different categories. For dossiers
that included a full pharmacoeconomic evaluation (i.e. cost-effectiveness and/ or
cost-utility analysis) in both countries, we compared in detail how the available
evidence was assessed to appraise societal value. RESULTS: Pharmacoeconomic
evaluations were more often available in Swedish dossiers due to many exemp-
tions in The Netherlands (mainly orphan and HIV drugs). Reimbursement dossiers
only provided a full economic evaluation in both countries for eleven drugs. The
reimbursement decision differed for four drugs, in which relatively more restric-
tions were observed. Although Dutch dossiers provided more details, all dossiers
included information of underlying clinical and economic studies. Comparators
were always reported. Using a similar comparator (8x) resulted in a similar (5x) and
a different (3x) therapeutic value judgement, while a different comparator (3x)
resulted twice in a similar judgement. Swedish ‘yes’ decisions (10x) were judged
cost-effective; ‘no’ decisions (two for one drug) were judged cost-ineffective. Dutch
‘yes’ decisions (9x, including two second decisions) were evaluated sufficiently (3x),
reasonably (1x), moderately (2x), and insufficiently (3x) founded pharmacoeco-
nomic evidence; all ‘no’ decisions (4x) were insufficiently founded. Appraisal ele-
ments were descriptively reported. The (high) severity of the disease was explicitly
mentioned in three overlapping cases. However, the actual influence of disease
severity on the final ‘yes’ decision remained unclear. CONCLUSIONS: Both coun-
tries make their reimbursement reports publicly available. Although the assess-
ment is reasonable transparent, both countries could improve transparency of the
appraisal process by more explicitly showing the actual role of each different (so-
cietal) criterion in drug reimbursement decision making.
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OBJECTIVES: With the current English NHS reforms will the new Clinical Commis-
sioning Groups (CCGs) follow an Italian type regional approach to enable patient
access to innovative and premium priced medicines when implementing patient
access schemes. METHODS: We reviewed the current structures of the first wave
CCGs and their association with the local oncology networks, new commissioning
support bodies and oncology centres to assess the practicality of implementing
current patient access schemes. We also reviewed new schemes approved by the
Italian medicines agency, AIFA, to accelerate reimbursement for new drugs espe-
cially when there is limited availability at launch. RESULTS: It is clear that the
suggested circa 200 proposed CCGs will have limited resources to fund suitable
management structures to run risk share/patient access scheme effectively. Spend
on pharmaceuticals, especially with public and physician demand, for innovative
premium cost cancer treatments, will now be led and influenced by General Prac-
titioners (GPs). The critical question facing family GPs will be how can they address
the funding of these high cost treatments yet still satisfy patient demand. One
approach that could be adopted to a new type of patient access scheme is now
being lead by AIFA who have developed an approach to enhance the reimburse-
ment potential of innovative anti-cancer medicines. CONCLUSIONS: The new
commissioning support bodies recently appointed by the English Department of
Health’s, National Commissioning Board, could easily follow the Italian suggested
approach; to help provide decision-making GPs with a framework to assess new
premium prices medicines, outside of the current support provided by NICE and
the Patient Access Scheme Liaison Unit.
RE4
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OBJECTIVES: Coverage decision processes determine the accessibility of health
technologies. Cost-effectiveness considerations have been identified to explain
decision outcomes. Beyond the evidence, outcomes may be influenced by the pro-
cess configurations used by decison makers. The aim of this exploratory study was
to analyse the influences of transparency, stakeholder participation, scientific
rigour of assessment and evidence judgments on decision outcomes in coverage
decision-making. METHODS: Using survey data of 77 decisions from 13 countries,
we examined whether outcomes differ by 14 variables that describe components of
coverage decision-making and the technology considered for coverage. Neglecting
the level of reimbursement, we analysed the likelihood of committees to cover a
technology, i.e. positive (including partial coverage) vs. negative coverage deci-
sions. We performed non-parametric univariate statistical tests and binomial lo-
gistic regression. To identify influences on decision outcomes, we applied a step-
wise variable selection procedure. RESULTS: We identified associations between
the decision outcome and the following variables: the technology is a prescribed
medicine (p0.0097); the health condition is an endocrine, nutritional or metabolic
disease (p0.0311) and the judgment of the evidence after assessment (p0.0001).
The first estimation of the logistic regression model suggested a quasi-complete
separation for those decisions where effectiveness and costs/cost-effectiveness
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